Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis
Immunity, Inflammation and Disease · 2025-10 · 13 (10)
DOI: 10.1002/iid3.70289 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 16.10.2025. Verfasst von Seyed Hamid Pakzad Moghadam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Kerman, Iran. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, Antiviral Agents, Hydroxylamines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Remdesivir and molnupiravir have been approved and are being used as viable treatment options for patients with coronavirus disease 2019 (COVID‐19). This systematic review and meta‐analysis sought to evaluate and compare the safety and effectiveness of these two antiviral drugs in the treatment of COVID‐19.
Methods
An extensive search was conducted across several databases, including Web of Science, PubMed, the Cochrane Library, and medRxiv, up to July 1, 2024. To evaluate the risk of bias, a standardized bias assessment tool was used. Data from the selected studies were analyzed using Comprehensive Meta‐Analysis software.
Results
The analysis included data from 10 studies, encompassing a total of 5766 patients. According to the meta‐analysis, remdesivir and molnupiravir showed no statistically significant differences in mortality (odds ratio [OR] = 2.54, 95% confidence interval [CI]: 0.67, 9.57), hospitalizations (OR = 2.43, 95% CI: 0.81, 7.24), viral clearance rates (OR = 1.49, 95% CI: 0.64, 3.46), or average time to viral clearance (standardized mean difference = 0.02, 95% CI: −0.40, 0.46). However, the incidence of adverse events was lower in the remdesivir group (OR = 0.49, 95% CI: 0.26, 0.93). The certainty of evidence for these findings was evaluated and determined to be low or moderate.
Conclusion
The findings of this study suggest that remdesivir and molnupiravir have similar effectiveness in treating COVID‐19 outpatients; however, molnupiravir is associated with a higher rate of adverse events. Additional studies are required to enable a more thorough evaluation of these treatments for COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Kerman, Iran.
- Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Tehran, Iran.
ORCID-Profile: Saeed Khorramnia
Zitieren
APA
Moghadam, S. H. P., Sarkoohi, A., Navidi, Z., Amani, B., Amani, B., & Khorramnia, S. (2025). Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis. Immunity, Inflammation and Disease, 13(10). https://doi.org/10.1002/iid3.70289
Vancouver
Moghadam SHP, Sarkoohi A, Navidi Z, Amani B, Amani B, Khorramnia S. Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis. Immunity, Inflammation and Disease. 2025;13(10). doi:10.1002/iid3.70289
BibTeX
@article{Moghadam2025,
author = {Moghadam, Seyed Hamid Pakzad and Sarkoohi, Ali and Navidi, Zia and Amani, Bahman and Amani, Behnam and Khorramnia, Saeed},
title = {Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis},
journal = {Immunity, Inflammation and Disease},
year = {2025},
volume = {13},
number = {10},
doi = {10.1002/iid3.70289}
}
EUVIMED